MedTrace Logo

Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

NCT02865369 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2017-03-07

No results posted yet for this study

Summary

A study on regression of liver fibrosis assessed by transient elastography after Daclatasvir and Asunaprevir combined treatment in advanced fibrotic/cirrhotic patients with chronic hepatitis C genotype 1b Infection

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Daclatasvir and Asunaprevir

Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.

Sponsors & Collaborators

  • Seoul National University Boramae Hospital

    collaborator OTHER

  • Severance Hospital

    collaborator OTHER

  • Inha University Hospital

    collaborator OTHER

  • Korea University

    collaborator OTHER

  • Gachon University Gil Medical Center

    collaborator OTHER

  • Hanyang University Seoul Hospital

    collaborator OTHER

  • Ewha Womans University Mokdong Hospital

    collaborator OTHER

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Sang Gyune Kim

    lead OTHER

Principal Investigators

  • Sang Gyune Kim, Professor · Soonchunhyang University Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-12-31
Completion
2022-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02865369 on ClinicalTrials.gov